Search research articles
Contact Us
Filters
Showing results (1-10 of 6) with videos related to
Page
of 1
Sort By:
Journal of Biopharmaceutical Statistics
|
August 20, 2010
Bayesian adaptive dose-finding studies with delayed responses
Haoda Fu, David Manner
Journal of Neurosurgery
|
March 31, 2005
Upper basilar artery aneurysms: oculomotor outcomes in 163 cases
Hisham Al-Khayat, Haitham Al-Khayat, Jonathan White, et al.
Neurosurgery
|
December 25, 2004
Vertebral artery-posteroinferior cerebellar artery aneurysms: clinical and lower cranial nerve outcomes in 52 patients
Hisham Al-khayat, Haitham Al-Khayat, Joseph Beshay, et al.
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
Optimizing Drug Development Programs: Type 2 Diabetes Case Study
Zoran Antonijevic, Martin Kimber, David Manner, et al.
Pharmaceutical Statistics
|
July 31, 2013
Bayesian methods for design and analysis of safety trials
Karen L Price, H Amy Xia, Mani Lakshminarayanan, et al.
Nature Communications
|
May 1, 2025
Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study
Anja Koester, Derrick R Witcher, Mark Lee, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 6) with videos related to
Sort By:
Page
of 1
Journal of Biopharmaceutical Statistics
|
August 20, 2010
Bayesian adaptive dose-finding studies with delayed responses
Haoda Fu, David Manner
Journal of Neurosurgery
|
March 31, 2005
Upper basilar artery aneurysms: oculomotor outcomes in 163 cases
Hisham Al-Khayat, Haitham Al-Khayat, Jonathan White, et al.
Neurosurgery
|
December 25, 2004
Vertebral artery-posteroinferior cerebellar artery aneurysms: clinical and lower cranial nerve outcomes in 52 patients
Hisham Al-khayat, Haitham Al-Khayat, Joseph Beshay, et al.
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
Optimizing Drug Development Programs: Type 2 Diabetes Case Study
Zoran Antonijevic, Martin Kimber, David Manner, et al.
Pharmaceutical Statistics
|
July 31, 2013
Bayesian methods for design and analysis of safety trials
Karen L Price, H Amy Xia, Mani Lakshminarayanan, et al.
Nature Communications
|
May 1, 2025
Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study
Anja Koester, Derrick R Witcher, Mark Lee, et al.
Page
of 1